Targeting vector configuration and method of gene transfer influence targeted correction of theAPRT gene in Chinese hamster ovary cells

1993 ◽  
Vol 19 (4) ◽  
pp. 363-375 ◽  
Author(s):  
Rodney S. Nairn ◽  
Gerald M. Adair ◽  
Thomas Porter ◽  
Sandra L. Pennington ◽  
Debra G. Smith ◽  
...  
1989 ◽  
Vol 9 (4) ◽  
pp. 1754-1758
Author(s):  
T M Underhill ◽  
W F Flintoff

A methotrexate-resistant Chinese hamster ovary cell line deficient in methotrexate uptake has been complemented to methotrexate sensitivity by transfection with DNA isolated from either wild-type Chinese hamster ovary or human G2 cells. Primary and secondary transfectants regained the ability to take up methotrexate in a manner similar to that of wild-type cells, and in the case of those transfected with human DNA, to contain human-specific DNA sequences. The complementation by DNA-mediated gene transfer of this methotrexate-resistant phenotype provides a basis for the cloning of a gene involved in methotrexate uptake.


2021 ◽  
pp. 2000620
Author(s):  
Feiyang Zheng ◽  
Yoshinori Kawabe ◽  
Mai Murakami ◽  
Mamika Takahashi ◽  
Kyoka Nishihata ◽  
...  

1989 ◽  
Vol 9 (4) ◽  
pp. 1754-1758 ◽  
Author(s):  
T M Underhill ◽  
W F Flintoff

A methotrexate-resistant Chinese hamster ovary cell line deficient in methotrexate uptake has been complemented to methotrexate sensitivity by transfection with DNA isolated from either wild-type Chinese hamster ovary or human G2 cells. Primary and secondary transfectants regained the ability to take up methotrexate in a manner similar to that of wild-type cells, and in the case of those transfected with human DNA, to contain human-specific DNA sequences. The complementation by DNA-mediated gene transfer of this methotrexate-resistant phenotype provides a basis for the cloning of a gene involved in methotrexate uptake.


Pathology ◽  
1993 ◽  
Vol 25 (3) ◽  
pp. 268-276 ◽  
Author(s):  
Wanda B. Mackinnon ◽  
Marlen Dyne ◽  
Rebecca Hancock ◽  
Carolyn E. Mountford ◽  
Adrienne J. Grant ◽  
...  

Author(s):  
Shazid Md. Sharker ◽  
Md. Atiqur Rahman

Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.


Sign in / Sign up

Export Citation Format

Share Document